Are Cis-Spliced Fusion Proteins Pathological in More Aggressive Luminal Breast Cancer? | Oncotarget скачать в хорошем качестве

Are Cis-Spliced Fusion Proteins Pathological in More Aggressive Luminal Breast Cancer? | Oncotarget

Oncotarget #published this #editorial on June 12, 2023 in Volume 14, entitled, “Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?” by Chia-Chia Liu and Xiao-Song Wang from the UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; Department of Pathology, University of Pittsburgh, Pittsburgh, PA. ‪@pittofficial‬ #cancer #research #breastcancer #tumors #openaccess #openscience #peerreview #journal #publication #meded #publishing DOI - https://doi.org/10.18632/oncotarget.2... Correspondence to - Xiao-Song Wang - [email protected] Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/deta... Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, luminal B breast cancer, RAD51AP1-DYRK4, MEK inhibitor, chimerical transcript About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud -   / oncotarget   Facebook -   / oncotarget   Twitter -   / oncotarget   Instagram -   / oncotargetjrnl   YouTube -    / @oncotargetjournal   LinkedIn -   / oncotarget   Pinterest -   / oncotarget   Reddit -   / oncotarget   Media Contact [email protected] 18009220957